Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

359 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.
de Lédinghen V, Trimoulet P, Winnock M, Foucher J, Bourlière M, Desmorat H, Canva V, Capron D, Lévy S, Mion F, Mannant PR, Chêne G, Fleury H, Couzigou P, Bernard PH; French Multicenter Study Group. de Lédinghen V, et al. Among authors: bourliere m. J Hepatol. 2002 May;36(5):672-80. doi: 10.1016/s0168-8278(02)00026-0. J Hepatol. 2002. PMID: 11983451 Clinical Trial.
Prevention of relapse in patients with chronic non-A, non-B/C hepatitis who respond to alpha-interferon. A controlled multicenter trial of low-dose maintenance therapy. Groupe d'Etude Multicentrique de l'Interféron dans les Hépatites.
Valla D, Babany G, Ouzan D, Trépo C, Bourlière M, Calès P, Payen JL, Couzigou P, Buffet C, Michel P, et al. Valla D, et al. Among authors: bourliere m. J Hepatol. 1994 Nov;21(5):774-8. doi: 10.1016/s0168-8278(94)80238-6. J Hepatol. 1994. PMID: 7890893 Clinical Trial.
A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France.
Pol S, Couzigou P, Bourlière M, Abergel A, Combis JM, Larrey D, Tran A, Moussalli J, Poupon R, Berthelot P, Bréchot C. Pol S, et al. Among authors: bourliere m. J Hepatol. 1999 Jul;31(1):1-7. doi: 10.1016/s0168-8278(99)80157-3. J Hepatol. 1999. PMID: 10424277 Clinical Trial.
[Do general practitioners want to manage chronic hepatitis C and take part in hepatitis C health networks? A national survey].
Babany G, Bourlière M, Chevalier H, Chousterman M, Couzigou P, Desmorat H, Dhumeaux D, Doffoël M, Gournay J, Loiseau D, Mercet P, Moussalli J, Trépo C, Tucat G, Doan Tran D, Saint-Marc-Girardin MF. Babany G, et al. Among authors: bourliere m. Gastroenterol Clin Biol. 1999 Dec;23(12):1289-95. Gastroenterol Clin Biol. 1999. PMID: 10642617 Free article. French.
Hepatitis C virus genotyping based on 5' noncoding sequence analysis (Trugene).
Halfon P, Trimoulet P, Bourliere M, Khiri H, de Lédinghen V, Couzigou P, Feryn JM, Alcaraz P, Renou C, Fleury HJ, Ouzan D. Halfon P, et al. Among authors: bourliere m. J Clin Microbiol. 2001 May;39(5):1771-3. doi: 10.1128/JCM.39.5.1771-1773.2001. J Clin Microbiol. 2001. PMID: 11325988 Free PMC article.
[Hepavir, the first observational study of one cohort of patients treated with alpha-2a interferon, monotherapy. Evaluation of asthenia and its social consequences].
Roudot-Thoraval F, Abergel A, Allaert F, Bourlière M, Desmorat H, Fagnani F, Fontanges T, Hanana A, Pol S, Zarski JP, Rousseaux C, Gandossi C, Samelson L, Dole S, Dantin S, Eberlé F, Saint-Marc-Girardin MF; Groupe d'Etude Pour Hépavir. Roudot-Thoraval F, et al. Among authors: bourliere m. Gastroenterol Clin Biol. 2001 Dec;25(12):1061-6. Gastroenterol Clin Biol. 2001. PMID: 11910986 Free article. French.
359 results